Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Up 157.9% in July

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 23,281 shares, an increase of 157.9% from the July 15th total of 9,026 shares. Based on an average trading volume of 69,598 shares, the short-interest ratio is presently 0.3 days.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS:OPHLY opened at $5.01 on Friday. Ono Pharmaceutical has a 12-month low of $3.55 and a 12-month high of $5.75. The company’s fifty day moving average is $4.85 and its two-hundred day moving average is $5.03.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.